FDA approves Biogen Idec's multiple sclerosis drug
from The Boston Globe
Scrambling to stay ahead of the competition in bringing multiple sclerosis drugs to market, Biogen Idec Inc. won U.S. regulatory approval to sell a new type of injectable drug that treats adults with the most common form of the neurodegenerative disease. Food and Drug Administration regulators approved the Cambridge biotech’s application to market the drug, called Plegridy, as a longer-lasting treatment for U.S. patients with relapsing-remitting multiple sclerosis.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063